Cancer Medicines: What Is Essential and Affordable in India?
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
ppublish
Résumé
The WHO essential medicines list (EML) guides selection of drugs for national formularies. Here, we evaluate which medicines are considered highest priority by Indian oncologists and the extent to which they are available in routine practice. This is a secondary analysis of an electronic survey developed by the WHO EML Cancer Medicine Working Group. The survey was distributed globally using a hierarchical snowball method to physicians who prescribe systemic anticancer therapy. The survey captured the 10 medicines oncologists considered highest priority for population health and their availability in routine practice. The global study cohort included 948 respondents from 82 countries; 98 were from India and 67 were from other low- and middle-income countries. Compared with other low- and middle-income countries, the Indian cohort was more likely to be medical oncologist (70% Most high-priority cancer medicines identified by Indian oncologists are generic chemotherapy agents that provide substantial improvements in survival and are already included in WHO EML. Access to these treatments remains limited by major financial burdens experienced by patients. This is particularly acute within the private health system. Strategies are urgently needed to ensure that high-quality cancer care is affordable and accessible to all patients in India.
Identifiants
pubmed: 35853192
doi: 10.1200/GO.22.00060
pmc: PMC9812506
doi:
Substances chimiques
Antineoplastic Agents
0
Drugs, Essential
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200060Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/W023903/1
Pays : United Kingdom
Références
PLoS One. 2018 Feb 26;13(2):e0193320
pubmed: 29481563
JCO Glob Oncol. 2020 Jul;6:1063-1075
pubmed: 32673076
Value Health. 2019 May;22(5):593-600
pubmed: 31104740
J Glob Oncol. 2018 Sep;(4):1-11
pubmed: 29244632
Lancet Oncol. 2014 May;15(6):e205-12
pubmed: 24731885
Front Pharmacol. 2013 May 07;4:57
pubmed: 23675348
ESMO Open. 2021 Jun;6(3):100166
pubmed: 34087744
Lancet Oncol. 2017 Jul;18(7):887-894
pubmed: 28583794
JAMA Oncol. 2021 May 01;7(5):728-734
pubmed: 33764385
Ann Oncol. 2016 Aug;27(8):1423-43
pubmed: 27457309
J Oncol Pract. 2018 May;14(5):e280-e294
pubmed: 29601250
Int J Equity Health. 2018 May 31;17(1):69
pubmed: 29855334
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Lancet Oncol. 2021 Dec;22(12):e541-e549
pubmed: 34856151
Curr Oncol. 2019 Apr;26(2):89-93
pubmed: 31043808
Lancet Oncol. 2019 Jun;20(6):757-758
pubmed: 31162087
Lancet Oncol. 2021 Oct;22(10):1367-1377
pubmed: 34560006
Lancet Oncol. 2014 May;15(6):e223-33
pubmed: 24731888
Health Policy. 2007 Oct;83(2-3):304-13
pubmed: 17379351